Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

CHRONIC MYELOGENOUS LEUKEMIA

Living, not just surviving, with chronic myeloid leukemia – quality of life to the front of the line

Leukemia volume 39, pages 1056–1057 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

Chronic myeloid leukemia (CML) therapy has come a long way over the last three decades [1]. From a disease where curative options were available to a small percentage of the newly diagnosed patients and even then, with the possibility of significant treatment-related problems, survival is now close to that of age-matched controls in the general population if diagnosed in the chronic phase, patient compliance is good, and the drug is available [2]. Yes, we can debate improvements of a few percent being worth using very new and much more expensive drugs that are not available to much of the world, but we now have a disease where the disease-free-survival is better than overall survival, indicating that people are dying not unexpectedly, but not usually not from CML!

Major improvements in the management of CML, both in terms of drugs available and without a doubt, our ability to monitor disease response or loss of response with molecular technology, are now routinely available and have made this easier on both the patient and the treating physician [3]. One would think that this along with the survival improvement, would be the issue that would give patients the most content. Recent patient-directed surveys have indicated that this may not be true and that what we as physicians consider to be the most important, are often not the same for patients.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10:117. https://doi.org/10.3390/cells10010117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7. https://doi.org/10.1200/JCO.2015.66.2866.

    Article  CAS  PubMed  Google Scholar 

  3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191–212. https://doi.org/10.1002/ajh.27443.

    Article  CAS  PubMed  Google Scholar 

  4. Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:80–5. https://doi.org/10.1007/s11899-016-0306-5.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhang Q, Li Z, Hou Y, Dang H, Chen J, Liang L, et al. Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Ann Palliat Med. 2022;11:1336–50. https://doi.org/10.21037/apm-22-158.

    Article  PubMed  Google Scholar 

  6. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. https://doi.org/10.1016/j.blre.2022.100968.

    Article  CAS  PubMed  Google Scholar 

  7. Yu L, Wang H, Gale RP, Qin Y, Lai Y, Shi H, et al. Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. Cancer Res Clin Oncol. 2022;148:449–59. https://doi.org/10.1007/s00432-021-03624-4.

    Article  CAS  Google Scholar 

  8. Jiang Q, Wang H, Yu L, Gale RP. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017;143:2619–30. https://doi.org/10.1007/s00432-017-2517-0.

    Article  PubMed  Google Scholar 

  9. Abruzzese E, Trawinska MM, De Fabritiis P, Bernardi S. SOHO state of the art updates and next questions: chronic myeloid leukemia and pregnancy: “Per Aspera Ad Astra”. Clin Lymphoma Myeloma Leuk. 2024;24:214–23. https://doi.org/10.1016/j.clml.2023.11.011.

    Article  PubMed  Google Scholar 

  10. Chen EY, Dahlén T, Stenke L, Björkholm M, Hao S, Dickman PW, et al (2024) Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia. Eur J Haematol. https://doi.org/10.1111/ejh.14328.

  11. Smit Y, Metsemakers SJJPM, Janssen JJWM, Posthuma EFM, Walraven I, Hermens RPMG, et al. Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures. Lancet Haematol. 2023;10:e849–e859. https://doi.org/10.1016/S2352-3026(23)00173-4.

    Article  CAS  PubMed  Google Scholar 

  12. Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep. 2021;16:491–9. https://doi.org/10.1007/s11899-021-00656-y.

    Article  PubMed  Google Scholar 

  13. Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114:160–4. https://doi.org/10.1093/jnci/djab184.

    Article  CAS  PubMed  Google Scholar 

  14. Russo D, Malagola M, Polverelli N, Farina M, Re F, Bernardi S. Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient. Ther Adv Hematol. 2023;14:20406207231216077. https://doi.org/10.1177/20406207231216077.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Clements J, Fleischman A, Lerner V, Ruiz C. The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist. Future Oncol. 2023;19:1197–208. https://doi.org/10.2217/fon-2022-1267.

    Article  CAS  PubMed  Google Scholar 

  16. Rabian F, Lengline E, Rea D. Towards a personalized treatment of patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2019;14:492–500. https://doi.org/10.1007/s11899-019-00546-4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Copland M. Is There a role for dose modification of TKI therapy in CML? Curr Hematol Malig Rep. 2019;14:337–45. https://doi.org/10.1007/s11899-019-00524-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

    Jeffrey H. Lipton

  2. Departement Medoc-Universitaire d’Hematologie, Paris, France

    Delphine Rea

Authors
  1. Jeffrey H. Lipton
    View author publications

    Search author on:PubMed Google Scholar

  2. Delphine Rea
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey H. Lipton.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lipton, J.H., Rea, D. Living, not just surviving, with chronic myeloid leukemia – quality of life to the front of the line. Leukemia 39, 1056–1057 (2025). https://doi.org/10.1038/s41375-025-02548-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-025-02548-z

Search

Advanced search

Quick links